Comprehensive genomic profiling testing in Japanese castration-resistant prostate cancer patients: results of a single-center retrospective cohort study

被引：1

作者：

Fukushima, Takafumi ^{[1
]}

Goto, Keisuke ^{[1
]}

Hayashi, Tetsutaro ^{[1
]}

Ikeda, Kenichiro ^{[1
]}

Hatayama, Tomoya ^{[1
]}

Yamanaka, Ryoken ^{[1
]}

Iwane, Kyosuke ^{[1
]}

Tasaka, Ryo ^{[1
]}

Kohada, Yuki ^{[1
]}

Takemoto, Kenshiro ^{[1
]}

Kobatake, Kohei ^{[1
]}

Goriki, Akihiro ^{[1
]}

Toshida, Asuka ^{[2
]}

Nakahara, Hikaru ^{[2
]}

Motonaga, Masanori ^{[3
]}

Tokumo, Kentaro ^{[4
]}

Fujii, Yasutoshi ^{[4
,5
]}

Hayes, C. Nelson ^{[5
]}

Okamoto, Wataru ^{[6
]}

Kubo, Toshio ^{[7
]}

Matsumoto, Takashi ^{[8
]}

Shiota, Masaki ^{[8
]}

Yamamoto, Noboru ^{[9
]}

Urabe, Yuji ^{[10
]}

Hiyama, Eiso ^{[11
,12
]}

Arihiro, Koji ^{[13
]}

Hinoi, Takao ^{[2
]}

Hinata, Nobuyuki ^{[1
]}

机构：

[1] Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Urol, 1-2-3 Kasumi,Minamiku, Hiroshima 7348551, Japan

[2] Hiroshima Univ Hosp, Genom Med Ctr, Dept Clin & Mol Genet, Hiroshima, Japan

[3] Hiroshima Univ Hosp, Dept Pharmaceut Serv, Hiroshima, Japan

[4] Hiroshima Univ Hosp, Dept Clin Oncol, Hiroshima, Japan

[5] Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Gastroenterol, Hiroshima, Japan

[6] Hiroshima Univ Hosp, Canc Treatment Ctr, Hiroshima, Japan

[7] OkayamaUnivers Hosp, Ctr Clin Oncol, Okayama, Japan

[8] Kyushu Univ, Grad Sch Med Sci, Dept Urol, Fukuoka, Japan

[9] Natl Canc Ctr, Dept Expt Therapeut, Tokyo, Japan

[10] Hiroshima Univ Hosp, Dept Gastrointestinal Endoscopy & Med, Hiroshima, Japan

[11] Hiroshima Univ Hosp, Dept Pediat Surg, Hiroshima, Japan

[12] Hiroshima Univ, Nat Sci Ctr Basic Res & Dev, Hiroshima, Japan

[13] Hiroshima Univ Hosp, Dept AnatomicalPathol, Hiroshima, Japan

来源：

JAPANESE JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 54卷 / 02期

关键词：

castration-resistant prostate cancer; comprehensive genome profiling testing; next-generation sequencing; CDK12; chemotherapy; POSITIVE SOLID TUMORS; INCREASED SURVIVAL; DOCETAXEL; PREDNISOLONE; MITOXANTRONE; ABIRATERONE;

D O I：

10.1093/jjco/hyad148

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Objective Comprehensive genomic profiling testing using a hybrid-capture next-generation sequencing is commonly used in clinical practice to employ precision medicine in cancer treatment worldwide. In this study, we aimed to analyze the profiles obtained using comprehensive genomic profiling testing that was performed in Japanese castration-resistant prostate cancer patients and to discuss the genetic findings in a real-world setting.Methods A total of 60 cases and 57 castration-resistant prostate cancer patients underwent comprehensive genomic profiling testing between 1 January 2021 and 31 December 2022. Four types of comprehensive genomic profiling testing were selected, and clinically significant cancer-specific gene alterations were identified.Results The median age of patients was 74 years, and the median prostate-specific antigen value at the time of submission was 18.6 ng/ml. Fifty-seven (95%) of 60 cases were metastatic castration-resistant prostate cancers, and 3 cases (5%) were non-metastatic. Among all genetic alterations, androgen-receptor alteration was the most frequently detected in 17 cases (28.3%), followed by 15 cases of TP53 (25.0%), 14 cases of CDK12 (23.3%), 10 cases of phosphatase and tensin homolog (16.7%) and 9 cases of ATM (15.0%) mutations. A total of 13 patients (21.7%) received systemic therapy according to the comprehensive genomic profiling testing results. Overall, the survival rate was significantly greater in the group treated through systemic therapy based on comprehensive genomic profiling testing compared with the group without new therapeutic treatment (P = 0.041).Conclusions Comprehensive genomic profiling testing is recommended in castration-resistant prostate cancer patients identified as resistant to standard therapy as this can provide a new therapeutic option. Comprehensive genomic profiling testing is useful for the selection of treatment for Japanese patients with castration-resistant prostate cancer.

引用

页码：175 / 181

页数：7

共 50 条

[1] Docetaxel rechallenge in metastatic castration-resistant prostate cancer: A retrospective, single-center study
Byeon, Seonggyu
Kim, Hyera
Kim, Jinchul
Kwon, Minsuk
Hur, Joon Young
Jeon, Hwang Gyun
Jeon, Seong Soo
Lee, Hyun Moo
Park, Se Hoon
INVESTIGATIVE AND CLINICAL UROLOGY, 2020, 61 (06) : 588 - 593
[2] Comprehensive genomic profiling of Japanese patients with thoracic malignancies: A single-center retrospective study
Hirakawa, Tetsu
Doi, Mihoko
Hamai, Kosuke
Katsura, Ryo
Miyake, Shinya
Fujita, Suguru
Ueno, Sayaka
Masuda, Ken
Tanimoto, Takuya
Nishisaka, Takashi
Hinoi, Takao
Hirasawa, Akira
Ishikawa, Nobuhisa
RESPIRATORY INVESTIGATION, 2023, 61 (06) : 746 - 754
[3] Efficacy of cabazitaxel in patients with metastatic castration-resistant prostate cancer: A single-center study in Japan
Yamamoto, Yoshiyuki
Ishii, Makoto
Yoshimura, Akihiro
Hayashi, Takuji
Kawamura, Norihiko
Nagahara, Akira
Nakai, Yasutomo
Nakayama, Masashi
Kakimoto, Ken-ichi
Nishimura, Kazuo
INTERNATIONAL JOURNAL OF UROLOGY, 2023, 30 (01) : 20 - 27
[4] Novel hormonal agents for metastatic Castration-Resistant Prostate Cancer: comparing outcomes. A single-center retrospective study
Jarimba, Roberto Saldanha
Eliseu, Miguel Nobre
Lima, Joao Pedroso
Quaresma, Vasco
Moreira, Pedro
Nunes, Pedro Coelho
da Silva, Edgar Tavares
Figueiredo, Arnaldo Jose
ARCHIVIO ITALIANO DI UROLOGIA E ANDROLOGIA, 2021, 93 (04) : 393 - 398
[5] Predictors of resistance to abiraterone acetate or enzalutamide in patients with metastatic castration-resistant prostate cancer in post-docetaxel setting: a single-center cohort study
Omrcen, Tomislav
Eterovic, Davor
Vrdoljak, Eduard
ANTI-CANCER DRUGS, 2020, 31 (07) : 742 - 746
[6] Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer Patients Progressing after Docetaxel: A Prospective Single-Center Study
Cicero, Giuseppe
De Luca, Rossella
Dorangricchia, Patrizia
Galvano, Antonio
Lo Re, Giuseppe
Serretta, Vincenzo
Dispensa, Nino
Dieli, Francesco
ONCOLOGY, 2017, 92 (02) : 94 - 100
[7] A multicenter phase I/II study of enzalutamide in Japanese patients with castration-resistant prostate cancer
Akaza, Hideyuki
Uemura, Hirotsugu
Tsukamoto, Taiji
Ozono, Seiichiro
Ogawa, Osamu
Sakai, Hideki
Oya, Mototsugu
Namiki, Mikio
Fukasawa, Satoshi
Yamaguchi, Akito
Uemura, Hiroji
Ohashi, Yasuo
Maeda, Hideki
Saito, Atsushi
Takeda, Kentaro
Naito, Seiji
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2016, 21 (04) : 773 - 782
[8] Efficacy and Safety Profile of Enzalutamide for Japanese Patients with Castration-resistant Prostate Cancer
Yamasaki, Mutsushi
Yuasa, Takeshi
Yamamoto, Shinya
Hayashi, Tatsuro
Ogawa, Masahiro
Sakura, Mizuaki
Masuda, Hitoshi
Fukui, Iwao
Yonese, Junji
ANTICANCER RESEARCH, 2016, 36 (01) : 361 - 365
[9] Alternative antiandrogen therapy in patients with castration-resistant prostate cancer: A single-center experience
Okegawa, Takatsugu
Nutahara, Kikuo
Higashihara, Eiji
INTERNATIONAL JOURNAL OF UROLOGY, 2010, 17 (11) : 950 - 955
[10] A Single-center Retrospective Analysis of the Effect of Radium-223 (Xofigo) on Pancytopenia in Patients with Metastatic Castration-resistant Prostate Cancer
Skelton, William P.
Dibenedetto, Samantha W.
Pang, Shiyi S.
Pan, Kelsey
Barish, Acob L.
Nwosu-Iheme, Adaeze
Dang, Long
CUREUS JOURNAL OF MEDICAL SCIENCE, 2020, 12 (01)

← 1 2 3 4 5 →